These findings highlight the pivotal role of microglia in GBM pathogenesis, suggesting that targeting TREM2, CX3CR1, and CSF1R may offer novel strategies to counteract microglia-driven immune suppression and enhance anti-tumor immunity. The gene discussed is CSF1R; the disease is neoplasm.